Discontinued — last reported Q2 '23
Sachem Capital Corp. Free cash flow increased by 64.2% to $7.06M in Q2 2023 compared to the prior quarter. This is a positive signal — higher values indicate stronger performance for this metric.
An increase suggests improved operational efficiency or reduced capital intensity, providing more flexibility for capital allocation. A decrease may indicate higher investment in R&D or infrastructure, or potential challenges in converting earnings into cash.
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and m...
Large-cap medical device and pharmaceutical peers typically maintain strong, positive free cash flow, though levels vary based on the intensity of R&D spending and the lifecycle stage of major product lines.
free_cash_flow| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | |
|---|---|---|---|---|---|---|---|---|---|
| Value | $2.61M | $11.20M | $10.43M | $7.55M | $0.00 | $4.60M | $453.50K | $4.30M | $7.06M |
| QoQ Change | — | +329.6% | -6.9% | -27.6% | -100.0% | — | -90.1% | +847.8% | +64.2% |
| YoY Change | — | — | — | — | -100.0% | -58.9% | -95.7% | -43.1% | — |